Skip to main content

Table 1 Correlation between clinical pathological characteristics of HCC patients and DARS2 expression

From: Upregulation of DARS2 by HBV promotes hepatocarcinogenesis through the miR-30e-5p/MAPK/NFAT5 pathway

Clinical pathological n DARS2 Proportion χ2 P value
characteristics high expression, n (%)
Gender     0.721 0.396
Male 74 36 48.65   
Female 6 4 66.67   
Age (years)     0.053 0.818
≥60 31 16 51.61   
<60 49 24 48.98   
Tumor size (cm)     6.084 0.014
≥2 43 27 62.79   
<2 37 13 35.14   
HBV infected     24.757 <0.0001
Yes 46 34 73.91   
No 34 6 17.65   
BCLC stages     15.245 0.002
0-A 21 6 28.57   
B 23 8 34.78   
C 21 13 61.90   
D 15 13 86.67   
Differentiation     22.667 <0.0001
Well 30 7 23.33   
Moderate 20 8 40.00   
Poor 30 25 83.33   
Liver cirrhosis     0.061 0.805
Yes 57 28 49.12   
No 23 12 52.17   
Intrahepatic metastasis     0.065 0.799
Yes 59 29 49.15   
No 21 11 52.38   
Distal metastasis     5.165 0.023
Yes 11 9 81.82   
No 69 31 44.93   
Portal vein invasion     7.813 0.005
Yes 21 16 76.19   
No 59 24 40.68   
AFP (μg/L)     2.515 0.284
≤25 8 3 37.50   
25–400 27 11 40.74   
>400 45 26 57.78